source
- Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipelineEli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
- Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emergeHelus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…